Overview of new developments in mysthenia gravis therapy

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction. Whilst a number of immune therapies have been established in recent decades, there is an ongoing need for safe and effective therapies, especially for treatment refractory patients. A number of recent trials have studied the effect of modern immunotherapies, targeting circulating immune cells, complement and Fc receptor inhibition. We will review these agents and the data relating to their use in MG.

Abstract licence: CC BY

17 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.